A Phase I, Randomized, Multi‐Dose Study to Evaluate the Enteric Selectivity and Safety of JAK Inhibitor, Lorpucitinib, in Healthy Participants
Open Access
- 29 January 2024
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 115 (5) , 1075-1084
Abstract
Janus kinase (JAK) signaling has been implicated in human inflammatory diseases, including psoriasis, rheumatoid arthritis, and inflammatory bowel disease. Lorpucitinib (JNJ‐64251330) is an oral, small molecule, pan‐JAK inhibitor. Unlike systemic JAK antagonists, lorpucitinib was found to have enteric (gut)‐selective properties, providing possible applications in diseases of the human gastrointestinal tract. Here, lorpucitinib was evaluated in a phase I, two‐part, dosing study (NCT04552197) to assess pharmacokinetics, pharmacodynamic biomarkers, and safety in healthy participants. In part 1, 24 participants were randomized to 1 of 4 treatment arms receiving either lorpucitinib (30 mg daily, 30 mg every 12 hours (q12h), or 75 mg q12h) or tofacitinib (5 mg q12h) for 5 days. Part 2 was a food‐effect study in which 12 participants received a single 75‐mg dose of lorpucitinib under either fasting or fed conditions. In part 1, plasma and gut tissue concentrations of lorpucitinib showed approximately dose‐proportional increases. At all doses, lorpucitinib concentrations were significantly higher (392‐ to 1928‐fold) in the gut mucosal biopsies vs. the corresponding plasma samples, demonstrating high enteric selectivity and significantly exceeding both the tissue concentrations (> 200‐fold) and tissue/plasma ratios observed with tofacitinib. JAK inhibition in biopsies was confirmed via reduction in pSTAT‐3 levels. In part 2, lorpucitinib plasma concentrations were detectable but at low levels, with no statistical differences in PK parameters between the fed and fasted groups. Lorpucitinib was safe and well‐tolerated, and the data may be useful in designing studies to evaluate lorpucitinib in patients with JAK/STAT‐driven gastrointestinal diseases.Keywords
Funding Information
- Janssen Research and Development
This publication has 25 references indexed in Scilit:
- Safety of Janus Kinase Inhibitors in Inflammatory Bowel DiseasesDrugs, 2023
- Upadacitinib Therapy Reduces Ulcerative Colitis Symptoms as Early as Day 1 of Induction TreatmentClinical Gastroenterology and Hepatology, 2022
- Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance StudiesClinical Pharmacology & Therapeutics, 2022
- Quantitative Mass Spectrometry Imaging to Study Drug Distribution in the Intestine Following Oral DosingAnalytical Chemistry, 2021
- Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine ProgrammeJournal of Crohn's and Colitis, 2020
- Discovery of a Gut-Restricted JAK Inhibitor for the Treatment of Inflammatory Bowel DiseaseJournal of Medicinal Chemistry, 2020
- A Macromolecular Janus Kinase (JAK) Inhibitor Prodrug Effectively Ameliorates Dextran Sulfate Sodium-Induced Ulcerative Colitis in MicePharmaceutical Research, 2019
- Evaluation of the Short‐, Mid‐, and Long‐Term Effects of Tofacitinib on Lymphocytes in Patients With Rheumatoid ArthritisArthritis & Rheumatology, 2018
- Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trialThe Lancet Haematology, 2017
- The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteersThe Journal of Clinical Pharmacology, 2014